ROIV vs VTRS: Which Stock Is the Better Buy?
Roivant Sciences Ltd. and Viatris Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ROIV vs VTRS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Roivant Sciences Ltd. (ROIV) | Viatris Inc. (VTRS) | |
|---|---|---|
| Market cap | $20.5B | $20.4B |
| Revenue (latest FY) | $8.26M | $14.30B |
| Net income (latest FY) | $-299.77M | $-3.51B |
| Revenue growth (5y CAGR) | -19.1% | 3.7% |
| Net margin | -3629.2% | -24.6% |
| Return on equity | -6.6% | -23.9% |
| P/E ratio | — | — |
| Dividend yield | — | 2.7% |
| Profitable years (of last 10) | 1 | 4 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ROIV vs VTRS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ROIV's full financials → Open VTRS's full financials →More comparisons
Frequently asked questions
Which is bigger, ROIV or VTRS?
Roivant Sciences Ltd. is larger by market capitalization — $20.5B versus $20.4B.
Which grows faster, ROIV or VTRS?
Over the last five fiscal years, Viatris Inc. grew revenue faster — 3.7%/yr versus -19.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ROIV fundamentals → · VTRS fundamentals → · All 1,500+ companies → · Free screener →